# National Institutes of Health Funding for RNA Vaccine Research **Authors:** Anirudha S. Chandrabhatla, Adishesh K. Narahari, Kevin Jin, Benjamin Mazurek, Taison D. Bell PMC · DOI: 10.1001/jamanetworkopen.2026.0046 · JAMA Network Open · 2026-03-02 ## TL;DR This study examines how the National Institutes of Health funds research on RNA vaccines. ## Contribution The paper provides an analysis of NIH funding trends and allocation for RNA vaccine research. ## Key findings - The study identifies patterns in NIH funding for RNA vaccine research. - It highlights the extent of federal investment in this area of biomedical research. ## Abstract This cross-sectional study describes the state of National Institutes of Health funding for research related to RNA vaccines. ## Full-text entities - **Diseases:** hematologic malignant neoplasms (MESH:D019337), ARDS (MESH:D012128), tropical viruses (MESH:D004802), Cancer (MESH:D009369), Allergy (MESH:D004342), hepatitis (MESH:D056486), Infectious Diseases (MESH:D003141), DVT (OMIM:612862), HIV (MESH:D015658), bacterial, fungal, and parasitic infections (MESH:D009181), deep vein thrombosis (MESH:D020246), COVID-19 (MESH:D000086382) - **Species:** human metapneumovirus (no rank) [taxon 162145], Human immunodeficiency virus 1 (no rank) [taxon 11676], Respiratory syncytial virus (no rank) [taxon 12814], Homo sapiens (human, species) [taxon 9606] ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954538/full.md ## References 6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954538/full.md --- Source: https://tomesphere.com/paper/PMC12954538